
Bruck Kifle
Examiner (ID: 6836, Phone: (571)272-0668 , Office: P/1624 )
| Most Active Art Unit | 1624 |
| Art Unit(s) | 1624, 1611, 1622, 1202 |
| Total Applications | 3432 |
| Issued Applications | 2601 |
| Pending Applications | 218 |
| Abandoned Applications | 651 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 16549716
[patent_doc_number] => 10882865
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-01-05
[patent_title] => Pyrrolopyrimidine compounds and uses thereof for modulating glucocerebrosidase activity
[patent_app_type] => utility
[patent_app_number] => 16/555827
[patent_app_country] => US
[patent_app_date] => 2019-08-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9593
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 34
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16555827
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/555827 | Pyrrolopyrimidine compounds and uses thereof for modulating glucocerebrosidase activity | Aug 28, 2019 | Issued |
Array
(
[id] => 17005332
[patent_doc_number] => 20210236493
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-05
[patent_title] => FUSED TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE
[patent_app_type] => utility
[patent_app_number] => 17/266961
[patent_app_country] => US
[patent_app_date] => 2019-08-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25935
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17266961
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/266961 | Fused tricyclic compounds and uses thereof in medicine | Aug 26, 2019 | Issued |
Array
(
[id] => 15209695
[patent_doc_number] => 20190367534
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-12-05
[patent_title] => MUTANT KRAS INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 16/540757
[patent_app_country] => US
[patent_app_date] => 2019-08-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8801
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16540757
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/540757 | Mutant KRas inhibitors | Aug 13, 2019 | Issued |
Array
(
[id] => 15963019
[patent_doc_number] => 20200165261
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-28
[patent_title] => CRYSTALLINE OF CAMPHORSULFONIC ACID SALT OF RUCAPARIB AND METHOD OF PREPARING OF TRICYCLIC COMPOUNDS, RUCAPARIB AND CRYSTALLINE OF CAMPHORSULFONIC ACID SALT OF RUCAPARIB
[patent_app_type] => utility
[patent_app_number] => 16/529224
[patent_app_country] => US
[patent_app_date] => 2019-08-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4980
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 37
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16529224
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/529224 | Crystalline of camphorsulfonic acid salt of rucaparib and method of preparing of tricyclic compounds, rucaparib and crystalline of camphorsulfonic acid salt of rucaparib | Jul 31, 2019 | Issued |
Array
(
[id] => 17829972
[patent_doc_number] => 20220267276
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-25
[patent_title] => NLRP MODULATORS
[patent_app_type] => utility
[patent_app_number] => 17/252623
[patent_app_country] => US
[patent_app_date] => 2019-07-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 133510
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -59
[patent_words_short_claim] => 14
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17252623
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/252623 | NLRP MODULATORS | Jul 1, 2019 | Abandoned |
Array
(
[id] => 19667432
[patent_doc_number] => 12180159
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-12-31
[patent_title] => Activators of the unfolded protein response
[patent_app_type] => utility
[patent_app_number] => 17/254771
[patent_app_country] => US
[patent_app_date] => 2019-07-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 50
[patent_figures_cnt] => 43
[patent_no_of_words] => 20515
[patent_no_of_claims] => 24
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 106
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17254771
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/254771 | Activators of the unfolded protein response | Jun 30, 2019 | Issued |
Array
(
[id] => 17126173
[patent_doc_number] => 20210300941
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-30
[patent_title] => BISPECIFIC DEGRADERS
[patent_app_type] => utility
[patent_app_number] => 17/255772
[patent_app_country] => US
[patent_app_date] => 2019-06-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17778
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 455
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17255772
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/255772 | Bispecific degraders | Jun 26, 2019 | Issued |
Array
(
[id] => 15977929
[patent_doc_number] => 10669272
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-06-02
[patent_title] => Substituted naphthyridinone compounds useful as T cell activators
[patent_app_type] => utility
[patent_app_number] => 16/452679
[patent_app_country] => US
[patent_app_date] => 2019-06-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 184160
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 724
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16452679
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/452679 | Substituted naphthyridinone compounds useful as T cell activators | Jun 25, 2019 | Issued |
Array
(
[id] => 15432297
[patent_doc_number] => 20200030331
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-01-30
[patent_title] => SUBSTITUTED PYRROLO[1,2-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
[patent_app_type] => utility
[patent_app_number] => 16/453109
[patent_app_country] => US
[patent_app_date] => 2019-06-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 51494
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16453109
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/453109 | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders | Jun 25, 2019 | Issued |
Array
(
[id] => 15363523
[patent_doc_number] => 20200017526
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-01-16
[patent_title] => METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES
[patent_app_type] => utility
[patent_app_number] => 16/448261
[patent_app_country] => US
[patent_app_date] => 2019-06-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27233
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16448261
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/448261 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | Jun 20, 2019 | Abandoned |
Array
(
[id] => 15324061
[patent_doc_number] => 20200002360
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-01-02
[patent_title] => METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES
[patent_app_type] => utility
[patent_app_number] => 16/442718
[patent_app_country] => US
[patent_app_date] => 2019-06-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12864
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16442718
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/442718 | Methods of preparing cytotoxic benzodiazepine derivatives | Jun 16, 2019 | Issued |
Array
(
[id] => 14929763
[patent_doc_number] => 20190300519
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-10-03
[patent_title] => Inhibitors of Beta-Hydroxylase for Treatment of Cancer
[patent_app_type] => utility
[patent_app_number] => 16/439253
[patent_app_country] => US
[patent_app_date] => 2019-06-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24103
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 583
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16439253
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/439253 | Inhibitors of beta-hydroxylase for treatment of cancer | Jun 11, 2019 | Issued |
Array
(
[id] => 14867921
[patent_doc_number] => 20190284202
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-09-19
[patent_title] => PROCESS FOR THE MANUFACTURE OF DIAZEPINE DERIVATIVES
[patent_app_type] => utility
[patent_app_number] => 16/434438
[patent_app_country] => US
[patent_app_date] => 2019-06-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6252
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 6
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16434438
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/434438 | PROCESS FOR THE MANUFACTURE OF DIAZEPINE DERIVATIVES | Jun 6, 2019 | Abandoned |
Array
(
[id] => 17954476
[patent_doc_number] => 11480576
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-10-25
[patent_title] => Conjugated oligomer-based macrocycles for live cell imaging
[patent_app_type] => utility
[patent_app_number] => 16/433243
[patent_app_country] => US
[patent_app_date] => 2019-06-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 22
[patent_no_of_words] => 6372
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 88
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16433243
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/433243 | Conjugated oligomer-based macrocycles for live cell imaging | Jun 5, 2019 | Issued |
Array
(
[id] => 15293495
[patent_doc_number] => 20190389883
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-12-26
[patent_title] => METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES
[patent_app_type] => utility
[patent_app_number] => 16/433117
[patent_app_country] => US
[patent_app_date] => 2019-06-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38353
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 44
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16433117
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/433117 | Methods of preparing cytotoxic benzodiazepine derivatives | Jun 5, 2019 | Issued |
Array
(
[id] => 17052103
[patent_doc_number] => 20210261537
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-26
[patent_title] => INHIBITORS OF SARM1
[patent_app_type] => utility
[patent_app_number] => 16/972670
[patent_app_country] => US
[patent_app_date] => 2019-06-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27684
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 276
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16972670
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/972670 | INHIBITORS OF SARM1 | Jun 5, 2019 | Pending |
Array
(
[id] => 18102363
[patent_doc_number] => 11542238
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-01-03
[patent_title] => Pyrimidine cyclohexenyl glucocorticoid receptor modulators
[patent_app_type] => utility
[patent_app_number] => 15/734525
[patent_app_country] => US
[patent_app_date] => 2019-06-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 27786
[patent_no_of_claims] => 32
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 303
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15734525
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/734525 | Pyrimidine cyclohexenyl glucocorticoid receptor modulators | Jun 2, 2019 | Issued |
Array
(
[id] => 17006978
[patent_doc_number] => 20210238139
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-05
[patent_title] => MODULATORS OF TRYPTOPHAN CATABOLISM
[patent_app_type] => utility
[patent_app_number] => 17/054885
[patent_app_country] => US
[patent_app_date] => 2019-05-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 57002
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17054885
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/054885 | MODULATORS OF TRYPTOPHAN CATABOLISM | May 30, 2019 | Abandoned |
Array
(
[id] => 16932301
[patent_doc_number] => 20210198190
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-01
[patent_title] => NOVEL SUBSTITUTED [1.1.1] BICYCLO COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 17/057921
[patent_app_country] => US
[patent_app_date] => 2019-05-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13251
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17057921
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/057921 | Substituted [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors | May 27, 2019 | Issued |
Array
(
[id] => 15178033
[patent_doc_number] => 20190359608
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-11-28
[patent_title] => TRICYCLIC HETEROCYCLIC COMPOUNDS AS STING ACTIVATORS
[patent_app_type] => utility
[patent_app_number] => 16/421881
[patent_app_country] => US
[patent_app_date] => 2019-05-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 61907
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -52
[patent_words_short_claim] => 2320
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16421881
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/421881 | Tricyclic heterocyclic compounds as sting activators | May 23, 2019 | Issued |